Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy
Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy
复制标题
DOI：
10.1046/j.1523-1747.1998.00411.x
复制
发表时间：
1998-12-01
影响因子：
6.5
通讯作者：
Hoon, DSB
中科院分区：
文献类型：
--
作者：
Okamoto, T;Irie, RF;Hoon, DSB
几种黑素体糖蛋白已被证明对人类具有抗原性。自身免疫性疾病白癜风、治疗引起的色素沉着不足和皮肤黑色素瘤患者的抗原特异性免疫反应的相关性尚未得到充分研究。我们检测了黑色素细胞自身抗原酪氨酸酶相关蛋白 2 (TRP-2) 的抗体反应，因为它在皮肤黑色素瘤和黑色素细胞中高度表达，合成了 TRP-2 重组蛋白用于蛋白质印迹和亲和抗 TRP-2 酶联免疫吸附测定。我们证明，恶性黑色素瘤、白癜风患者、 活性特异性免疫治疗引起的色素脱失具有显着的抗 TRP-2 IgG 滴度。白癜风患者的抗 TRP-2 IgG 反应水平最高。在接受含有 TRP-2 的多价黑色素瘤细胞疫苗治疗的黑色素瘤患者中观察到抗 TRP-2 IgG 反应的诱导和增强。主动特异性免疫疗法可以诱导和/或增强 TRP-2 IgG 抗体滴度。与预后不良的患者相比，发生色素沉着不足并在多价黑色素瘤细胞疫苗接种后生存率提高的黑色素瘤患者的抗 TRP-2 抗体反应显着增强。这项研究表明 TRP-2 自身抗原在人类中具有免疫原性。 TRP-2 抗体反应提供了白癜风患者的自身免疫反应和对诱导色素沉着不足的免疫治疗做出反应的黑色素瘤患者之间的联系。
Several rnelanosome glycoproteins have been shown to be antigenic in humans. Correlation of antigen-specific immune responses in patients with the autoimmune disease vitiligo, therapy-induced hypopigmentation, and cutaneous melanoma has not been well studied. We examined antibody responses to a melanocyte autoantigen, tyrosinase-related protein-2 (TRP-2), as it is highly expressed in cutaneous melanoma and melanocytes, TRP-2 recombinant protein was synthesized for western blot and affinity anti-TRP-2 enzyme-linked immunosorbent assay, We demonstrated that patients with malignant melanoma, vitiligo, and active-specific immunotherapy-induced depigmentation had significant anti-TRP-2 IgG titers. The highest level of anti-TRP-2 IgG response was found in vitiligo patients. Induction and enhancement of anti-TRP-2 IgG responses were observed in melanoma patients treated with a polyvalent melanoma cell vaccine containing TRP-2. Active-specific immunotherapy could induce and/or augment the TRP-2 IgG antibody titers. Melanoma patients who developed hypopigmentation and had improved survival after polyvalent melanoma cell vaccine had significantly augmented anti-TRP-2 antibody responses compared with patients with poor prognosis. This study demonstrates that TRP-2 autoantigen is immunogenic in humans. TRP-2 antibody responses provide a linkage between autoimmune responses by vitiligo patients and melanoma patients responding to immunotherapy who have induced hypopigmentation.